Stockscreener 앱 받기
16.19
0.50%
0.08
시간 외 거래:
16.19
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
Bicara Therapeutics: How InvestingPro’s overvaluation call led to 39% decline By Investing.com - Investing.com
Will Bicara Therapeutics Inc. stock continue dividend increases2026 world cup usa national team group stage playmakers pressing system winner prediction preview - Улправда
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of “Hold” from Analysts - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
What Drawdown Risk Means for Long Term Holders of Clean Science and Technology LimitedStock Buyback Announcements & Zero-Cost Stock Research by Professionals - earlytimes.in
Bicara Therapeutics (NASDAQ:BCAX) Trading 3.9% Higher – Here’s Why - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 3.9%Still a Buy? - MarketBeat
Straddle Buy Call Buy Put at same strikeEarnings Call Summaries & Exceptional Return Growth - bollywoodhelpline.com
Hyep Ivan, Bicara Therapeutics CFO, sells $168k in BCAX stock - Investing.com India
Hyep Ivan, Bicara Therapeutics CFO, sells $168k in BCAX stock By Investing.com - Investing.com Nigeria
Bicara Therapeutics (BCAX) Valuation After Dual Biotechnology Index Additions - Yahoo Finance
How Bicara's Dual Biotech Index Additions Will Impact Bicara Therapeutics (BCAX) Investors - simplywall.st
The Bull Case For Bicara Therapeutics (BCAX) Could Change Following Dual Inclusion In Major Biotech Indices - Yahoo Finance
Bicara Therapeutics Inc.(NasdaqGM: BCAX) added to NASDAQ Biotechnology Index - marketscreener.com
Bicara Therapeutics Inc.(NasdaqGM:BCAX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Is Bicara Therapeutics Inc. stock a defensive play in 2025July 2025 PostEarnings & Intraday High Probability Setup Alerts - Улправда
Can Bicara Therapeutics Inc. stock rebound after recent weaknessEarnings Overview Summary & Verified Swing Trading Watchlist - ulpravda.ru
Bicara Therapeutics (NASDAQ:BCAX) Raised to Hold at Mizuho - Defense World
Is Bicara Therapeutics Inc. stock trading at a premium valuationInsider Buying & AI Forecast for Swing Trade Picks - Улправда
Will Bicara Therapeutics Inc. stock deliver better than expected guidanceEarnings Recap Report & Weekly High Potential Alerts - Улправда
Published on: 2025-12-19 16:38:22 - Bölüm Sonu Canavarı
Bicara Therapeutics (NASDAQ:BCAX) Raised to "Hold" at Mizuho - MarketBeat
What makes Bicara Therapeutics Inc. stock attractive to growth fundsFed Meeting & Technical Pattern Recognition Alerts - Улправда
Can Bicara Therapeutics Inc. stock reach $100 price target2025 Earnings Impact & Long-Term Investment Growth Plans - ulpravda.ru
Mizuho Initiates Coverage of Bicara Therapeutics (BCAX) with Neutral Recommendation - Nasdaq
Mizuho Initiates Bicara Therapeutics at Neutral With $18 Price Target - marketscreener.com
Bicara Therapeutics (BCAX) Receives Neutral Rating from Mizuho | - GuruFocus
Mizuho initiates Bicara Therapeutics stock coverage with Neutral rating By Investing.com - Investing.com Canada
Mizuho initiates Bicara Therapeutics stock coverage with Neutral rating - Investing.com
Bicara Therapeutics initiated with a Neutral at Mizuho - TipRanks
Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 12,500 Shares - MarketBeat
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 - The Manila Times
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Bicara Therapeutics Earns Relative Strength Rating Upgrade - Investor's Business Daily
Bicara announces preliminary data from phase 1b cohort of ficerafusp alfa - MSN
There is no doubt that Bicara Therapeutics Inc (BCAX) ticks all the boxes. - setenews.com
Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Bicara stock maintains Buy rating at Stifel after ESMO-Asia data - Investing.com Australia
Published on: 2025-12-09 02:41:05 - moha.gov.vn
Promising Efficacy and Investment Potential for Bicara Therapeutics’ FICERA in Combination with Keytruda - TipRanks
Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Data and Strategic Valuation - TipRanks
Bicara Therapeutics Reports Promising Phase 1b Data - TipRanks
2.52%
0.07%
자본화:
|
볼륨(24시간):